Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Weight Management Benefit for Pediatric Members
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.305 alerts
Get alerted when Policy MDN.CP.PMN.305 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) when requested for chronic weight management in pediatric members through the EPSDT benefit; applies to Meridian Medicaid lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Pediatric GLP-1 Receptor Agonists
Initial Approval Criteria
Covered when ALL of the following are met (EPSDT route):
Per policy/criteria: documentation must be provided to support medical necessity.
Policy states 'Weight loss is a benefit exclusion and is not a covered benefit.' EPSDT requests are handled per criteria.
Continuation Therapy
Continued therapy:
Document excerpt indicates 'Not eligible for continued therapy.' Full context of continuation policy not present in this partial document.
Policy purpose and applicability
Policy guidance and applicability statements present in excerpt
Policy explains its role in coverage decisions and limitations.
Source describes the evidence and standards used to develop the policy.
Explicit statement that state Medicaid manual provisions prevail for Medicaid members.
Coadministration: coadministration with other liraglutide-, semaglutide-, tirzepatide-containing products or with any other GLP-1 receptor agonists is not recommended. Contraindications and boxed warnings that may affect clinical use include a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), prior hypersensitivity to liraglutide, semaglutide, tirzepatide, or any excipients, and a boxed warning for risk of thyroid C-cell tumors.
The provided excerpt does not list any additional specific clinical exclusions beyond the contraindications and limitations described elsewhere in the policy. Providers should refer to the full clinical policy and coverage documents for any member- or state-specific exclusionary provisions when preparing an authorization request.
Policy statement: weight loss is a benefit exclusion and is not a covered benefit. However, requests processed through the EPSDT benefit are considered under the policy's specified approval criteria.
The excerpt does not enumerate conditions explicitly labeled as 'not medically necessary.' The clinical policy is presented as a guide to medical necessity and directs that coverage determinations remain subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state and federal requirements.
Product Availability, Formulations, and Dosing
| Liraglutide (Saxenda) pre-filled multi-dose pens | 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg (6 mg/mL, 3 mL) |
| Semaglutide (Wegovy) pre-filled single-dose pens | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg |
| Tirzepatide (Zepbound) pre-filled single-dose pens and vials | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
Prior Authorization, Documentation, and Provider Responsibilities
Prior authorization required via EPSDT
Prior authorization is required through the EPSDT benefit for requests for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) when requested for chronic weight management in pediatric members.
Prior authorization rules for GLP-1 RAs
The clinical policy establishes prior authorization requirements for GLP-1 receptor agonists used for pediatric weight management; product availability, dosing, and applicable codes are specified elsewhere in the policy and used in authorization decisions.
- Product availability and dosing examples influence authorization decisions (see product availability and dosing sections).
- Specific billing or prior authorization code references are maintained elsewhere in the policy and are applied to requests for these agents.
Therapeutic alternatives (Appendix B)
Therapeutic alternatives are listed in Appendix B; the alternatives table provides preferred alternative therapies and notes that listed drugs may require prior authorization per formulary.
- Appendix B lists preferred alternative therapies and may include dosing examples.
- Alternatives may not be formulary agents for all lines of business and can require prior authorization.
Step therapy not specified in excerpt
The provided document excerpt does not specify any explicit step therapy requirements for pediatric GLP-1 RA weight management.
- No step therapy sequence or mandatory trials are described in the excerpt.
Submit clinical documentation with PA
Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other clinical information demonstrating the member meets all approval criteria.
- Documentation must show that the member meets the EPSDT/approval criteria outlined in the policy.
- Include relevant clinical data (e.g., BMI percentiles, age, prior treatments) as applicable to the request.
Follow standards of practice and plan rules
Providers must follow generally accepted standards of medical practice and applicable Health Plan administrative policies; this clinical policy is a guide to medical necessity and coverage is subject to coverage documents and state/federal requirements.
- Medical record documentation should be consistent with standard clinical practice and plan-level requirements.
- Coverage is subject to terms, exclusions, and limitations in the member's coverage documents.
Weight-loss exclusion; EPSDT pathway applies
The policy states that weight loss is a benefit exclusion and is not a covered benefit, but EPSDT weight management requests are handled through the EPSDT prior authorization criteria in this clinical policy.
- Even though weight loss is generally an exclusion, EPSDT requests may be considered when submitted with required documentation through EPSDT.
State Medicaid provisions may supersede policy
For Medicaid members, state Medicaid coverage provisions take precedence over this clinical policy; when state provisions conflict with this policy, failure to follow state Medicaid manual requirements may result in denial.
- Check the applicable state Medicaid manual for coverage provisions that may supersede this policy.
Clinical Background
GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) are indicated for use in combination with diet and increased physical activity to reduce and maintain weight loss in adults and in pediatric patients aged 12 years and older for specific agents; clinical use is subject to contraindications, boxed warnings, and dosing escalation as outlined in the full policy.
Key Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.